Aboriginal and Torres Strait Islander women experience inequitable cervical cancer outcomes including higher incidence and mortality rates than other Australian women. Cervical cancer can be prevented through human papillomavirus (HPV) vaccination, which is primarily delivered through school immunisation programmes and found to be very effective. However, Aboriginal and Torres Strait Islander adolescents have lower rates of HPV vaccination uptake compared with non-Indigenous adolescents.
This study explored the perspectives and experiences of HPV vaccination programme providers and school staff involved in the delivery of school-based HPV vaccination programmes for Aboriginal and Torres Strait Islander adolescents in Queensland.
This qualitative project recruited 10 maximally diverse schools to participate. We purposively invited immunisation programme providers and school staff associated with delivering or supporting and used a snowballing approach to recruitment. We used an Indigenist Research approach and an ecological model for health to centre Aboriginal and Torres Strait Islander experiences and priorities.
We interviewed 18 immunisation programme providers and school staff involved in delivery between 2020 and 2022. Interview topics included programme delivery and processes, engagement with Aboriginal and Torres Strait Islander adolescents and caregivers, factors impacting uptake and completion, and suggestions for improvement.
Stakeholders highlighted multilayered challenges navigating a school-based immunisation programme across health and education sectors, especially within the context of the COVID-19 pandemic. This included logistical barriers around programme coordination and scheduling, roles and responsibilities, and communication issues between schools, programme providers, caregivers and adolescents. Four themes were identified: (1) co-ordination of the clinic between schools and programme providers, (2) supporting Aboriginal and Torres Strait Islander families through the vaccination pathway, (3) HPV vaccination resources and (4) COVID-19 disruptions to HPV vaccination programme.
The findings suggest a need for better communication and coordination of the school-based clinic, including consideration of staff capacity and school resources; enhanced linkages with and support for Aboriginal and Torres Strait Islander student support staff and community organisations who play a critical role in supporting adolescents’ vaccination, and flexible methods of consent supported by culturally appropriate resources. These findings informed recommendations for improved practice and will contribute towards reaching Australia’s cervical cancer elimination targets.
To estimate the prevalence of urinary incontinence (UI) and its subtypes among nulliparous Chinese women with associated risk factors. The prevalence of UI among those living in urban or rural communities was also analysed with potential risk factors.
This is a secondary analysis of epidemiological survey data on UI in Chinese women. The original study was designed as a nationwide cross-sectional study involving 56 460 adult women conducted from October 2019 to December 2021.
Seven geographic regions of China.
Nulliparous women who were aged ≥20 years old and were permanent residents were included in this secondary analysis. Participants who had severe mental or physical disorders or were pregnant were excluded. Data on demographic characteristics, health status and medical history were collected.
The primary outcome was the prevalence of UI, whereas secondary outcome measures were adjusted odds ratios (aOR) for risk factor analysis.
A total of 6244 nulliparous women were included in the analysis. The prevalence of UI was 1.9% for nulliparous Chinese women, with stress, urgency and mixed UI being prevalent at 0.9%, 0.3% and 0.7%, respectively. The prevalence of UI was 2.1% and 1.6% for urban and rural subgroups. Abnormal body mass index was significantly associated with UI in the nulliparous group (underweight, aOR: 1.88, 95% CI: 1.03 to 3.45, p=0.041; overweight, aOR: 2.26, 95% CI: 1.37 to 3.73, p=0.001; and obesity, aOR: 3.64, 95% CI: 1.86 to 7.15, p
UI among nulliparous women deserves greater public attention. Abnormal body mass index, including underweight status, was found to be a risk factor for UI among Chinese nulliparous women. Further research is required to investigate the mechanism underlying the association between underweight status and UI.
The study was approved by Peking Union Medical College Ethics Committee (No. S-K970) and conducted according to the Declaration of Helsinki. All participants signed consent forms before data collection. A completed STROBE checklist detailing compliance with all 22 items is provided.
Allografts derived from live-birth tissue obtained with donor consent have emerged as an important treatment option for wound and soft tissue repairs. Placental membrane derived from the amniotic sac consists of the amnion and chorion, the latter of which contains the trophoblast layer. For ease of cleaning and processing, these layers are often separated with or without re-lamination and the trophoblast layer is typically discarded, both of which can negatively affect the abundance of native biological factors and make the grafts difficult to handle. Thus, a full-thickness placental membrane that includes a fully-intact decellularized trophoblast layer was developed for homologous clinical use as a protective barrier and scaffold in soft tissue repairs. Here, we demonstrate that this full-thickness placental membrane is effectively decellularized while retaining native extracellular matrix (ECM) scaffold and biological factors, including the full trophoblast layer. Following processing, it is porous, biocompatible, supports cell proliferation in vitro, and retains its biomechanical strength and the ability to pass through a cannula without visible evidence of movement or damage. Finally, it was accepted as a natural scaffold in vivo with evidence of host-cell infiltration, angiogenesis, tissue remodelling, and structural layer retention for up to 10 weeks in a murine subcutaneous implant model.